English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Metabolic syndrome (MS) is linked to cardiovascular risk. Recently published Adult Treatment Panel III (ATPIII) criteria provide a definition for diagnosis of MS. We analyzed the impact of the ATPIII-defined MS on left ventricular (LV) hypertrophy in treated hypertensive adults of the HyperGEN study. LV structure was examined by echocardiography in 912 treated hypertensive non-diabetic participants of the HyperGEN study (329 white and 583 African American), without prevalent cardiovascular disease. White participants were older (60 9yrs vs 51 10yrs; p 0.001) and had higher prevalence of MS (53.5% vs 36.2% p 0.001) as compared to African Americans. White participants with the metabolic syndrome (50% women) had similar age, blood pressure and heart rate as compared with non-MS participants (all p ns). After controlling for type of hypertensive medication and gender differences, white MS participants exhibited similar LV diastolic diameter (p ns), but higher values of relative wall thickness and LV mass/BSA as compared to non-MS whites (all p 0.05), with a significant higher prevalence of LV hypertrophy (27.4% vs 16.9%; p 0.05). African American participants with the metabolic syndrome (68.7% women) had similar age, blood pressure and heart rate as compared with non-MS participants (all p ns). After controlling for type of hypertensive medication and gender differences, MS participants exhibited similar LV diastolic diameter, relative wall thickness, LV mass (all p ns) as compared to non-MS. African Americans had a higher prevalence of LV hypertrophy (33%) than whites with no significant difference between the MS and the non-MS group. In treated hypertensive patients, ATPIII defined metabolic syndrome has a higher prevalence in whites than in African Americans. Presence of the MS is also associated with a significant higher prevalence of LV hypertrophy in whites, while no significant effect is found in African Americans where the high prevalence of LV hypertrophy is independent of the presence of ATPIII defined MS.

american journal of hypertension

ATPIII-defined metabolic syndrome is associated with prevalence of LV hypertrophy in white, but not in African American, treated hypertensives: the hypergen study